awmsg logo



bosutinib (Bosulif®)


Reference No. 2507

Publication date:
25/07/2018


Appraisal information

bosutinib (Bosulif®) 100 mg tablet
bosutinib (Bosulif®) 500 mg tablet


Company: Pfizer Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 23/07/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, bosutinib (Bosulif®) cannot be endorsed for use within NHS Wales for the treatment of newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.
Statement of Advice (SOA)
Download